Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial.
OBJECTIVE
To evaluate the efficacy and safety of capsule oxymatrine in the treatment of chronic hepatitis B.


METHODS
A randomised double-blind and placebo-controlled multicenter trial was conducted. Injection of oxymatrine was used as positive-control drug. A total of 216 patients with chronic hepatitis B entered the study for 24 weeks, of them 108 received capsule oxymatrine, 36 received injection of oxymatrine, and 72 received placebo. After and before the treatment, clinical symptoms, liver function, serum hepatitis B virus markers, and adverse drug reaction were observed.


RESULTS
Among the 216 patients, six were dropped off, and 11 inconsistent with the standard were excluded. Therefore, the efficacy and safety of oxymatrine in patients were analysed. In the capsule treated patients, 76.47% became normal in ALT level, 38.61% and 31.91% became negative both in HBV DNA and in HBeAg. In the injection treated patients, 83.33% became normal in ALT level, 43.33% and 39.29% became negative both in HBV DNA and in HBeAg. In the placebo treated patients, 40.00% became normal in ALT level, 7.46% and 6.45% became negative both in HBV DNA and in HBeAg. The rates of complete response and partial response were 24.51% and 57.84% in the capsule treated patients, and 33.33% and 50.00% in the injection treated patients, and 2.99% and 41.79% in the placebo treated patients, respectively. There was no significance between the two groups of patients, but both were significantly higher than the placebo. The adverse drug reaction rates of the capsule, injection and placebo were 7.77%, 6.67% and 8.82%, respectively. There was no statistically significant difference among them.


CONCLUSIONS
Oxymatrine is an effective and safe agent for the treatment of chronic hepatitis B.
Lu
Lun-Gen
LG
Shanghai Institute of Digestive Disease, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China. lulungen@online.sh.cn
Zeng
Min-De
MD
Mao
Yi-Min
YM
Li
Ji-Qiang
JQ
Wan
Mo-Bin
MB
Li
Cheng-Zhong
CZ
Chen
Cheng-Wei
CW
Fu
Qing-Chun
QC
Wang
Ji-Yao
JY
She
Wei-Min
WM
Cai
Xiong
X
Ye
Jun
J
Zhou
Xia-Qiu
XQ
Wang
Hui
H
Wu
Shan-Ming
SM
Tang
Mei-Fang
MF
Zhu
Jin-Shui
JS
Chen
Wei-Xiong
WX
Zhang
Hui-Quan
HQ
D000284:Administration, Oral; D000410:Alanine Transaminase / Q000097:blood; D000470:Alkaloids / Q000008:administration & dosage* / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D006514:Hepatitis B Surface Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D010919:Placebos; D011807:Quinolizines; D016896:Treatment Outcome; D000093842:Matrines
D000410:Alanine Transaminase; D000470:Alkaloids; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D010919:Placebos; D011807:Quinolizines; C037573:oxymatrine; D000093842:Matrines